Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 6/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 6/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2645838 | 0.88 | ALDH1A1 (0.49) | ALDH1A1GAAGFERPDK2P2RX7 | |
| SCHEMBL20214473 | 0.84 | GAA (0.49) | ALDH1A1GAAGFERPDK2CYP4F2 | |
| SCHEMBL2126752 | 0.84 | ALDH1A1 (0.60) | ALDH1A1GAAGFERPDK2CYP4F2 | |
| SCHEMBL1780814 | 0.83 | IDO1 (0.53) | ALDH1A1GAAGFERPDK2P2RX7 | |
| SCHEMBL20576241 | 0.83 | ALDH1A1 (0.48) | ALDH1A1GAAGFERPDK2CYP4F2 | |
| SCHEMBL6213644 | 0.82 | P2RX7 (0.47) | P2RX7NR3C2PTPN7DUSP3AR | |
| SCHEMBL1717077 | 0.82 | ALDH1A1 (0.56) | ALDH1A1GAAGFERPDK2CYP4F2 | |
| SCHEMBL30639470 | 0.82 | ALDH1A1 (0.56) | ALDH1A1GAAGFERPDK2CYP4F2 | |
| SCHEMBL2981821 | 0.81 | ALDH1A1 (0.51) | ALDH1A1GAAGFERPDK2CYP4F2 | |
| SCHEMBL8448706 | 0.81 | GAA (0.46) | ALDH1A1GAAGFERPDK2CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2455105-A2 | Bombesin analogues | Bayer Pharma Aktiengesellschaft (DE) | 2012-05-23 | — | — | EP | disclosed |
| EP-2289564-A2 | Derivatives of aniline as precursors for F18-labeling | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-03-02 | — | — | EP | disclosed |
| EP-2279759-A2 | Compounds and methods for 18F labeled agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-02-02 | — | — | EP | disclosed |
| US-20080292548-A1 | COMPOUNDS AND METHODS FOR 18F LABELED AGENTS | Lantheus Biosciences Ltd. (GB) | 2008-11-27 | — | — | US | disclosed |
| EP-1985624-A2 | Single step method of radiofluorination of biologically active compounds or biomolecules | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-10-29 | — | — | EP | disclosed |
| WO-2008028688-A2 | COMPOUNDS AND METHODS FOR 18F LABELED AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |
| US-7259166-B2 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1501815-B1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2006-11-22 | — | — | EP | disclosed |
| US-7105671-B2 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20060178429-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | CORBETT WENDY L | 2006-08-10 | — | — | US | disclosed |
| EP-1501815-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003095438-A9 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-12-23 | — | — | WO | disclosed |
| US-20030225283-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | CORBETT WENDY LEA (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2003095438-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178429-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | GCKR, GCK, PDXK | ALDH1A1 3003/4885GAA 585/4885GFER 1710/4885 |
| US-20080292548-A1 | COMPOUNDS AND METHODS FOR 18F LABELED AGENTS | QPCT, GBA2, GBA1 | ALDH1A1 2019/4885GAA 37/4885GFER 2579/4885 |
| US-20030225283-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | GCKR, GCK, PDXK | ALDH1A1 3003/4885GAA 585/4885GFER 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.